Eledoisin

Eledoisin (Eledone peptide) is a specific agonist of NK2 and NK3 receptors.

Product information

CAS Number: 69-25-0

Molecular Weight: 1188.40

Formula: C54H85N13O15S

Chemical Name: (3S)-3-[(2S)-6-amino-2-[(2S)-3-hydroxy-2-{[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidin-2-yl]formamido}propanamido]hexanamido]-3-{[(1S)-1-{[(1S)-1-{[(1S,2S)-1-[({[(1S)-1-{[(1S)-1-carbamoyl-3-(methylsulfanyl)propyl]carbamoyl}-3-methylbutyl]carbamoyl}methyl)carbamoyl]-2-methylbutyl]carbamoyl}-2-phenylethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

Smiles: CC(C)C[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCC(=O)N1)[C@@H](C)CC)C(=O)N[C@@H](CCSC)C(N)=O

InChiKey: AYLPVIWBPZMVSH-FCKMLYJASA-N

InChi: InChI=1S/C54H85N13O15S/c1-7-30(4)44(53(81)57-27-42(70)60-36(24-29(2)3)49(77)61-33(45(56)73)20-23-83-6)66-50(78)37(25-32-14-9-8-10-15-32)63-46(74)31(5)58-48(76)38(26-43(71)72)64-47(75)34(16-11-12-21-55)62-51(79)39(28-68)65-52(80)40-17-13-22-67(40)54(82)35-18-19-41(69)59-35/h8-10,14-15,29-31,33-40,44,68H,7,11-13,16-28,55H2,1-6H3,(H2,56,73)(H,57,81)(H,58,76)(H,59,69)(H,60,70)(H,61,77)(H,62,79)(H,63,74)(H,64,75)(H,65,80)(H,66,78)(H,71,72)/t30-,31-,33-,34-,35-,36-,37-,38-,39-,40-,44-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: H2O : 18.15 mg/mL (15.27 mM; Need ultrasonic and warming).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Eledoisin (Eledone peptide) increases the value recorded under basal conditions by 24.5±3.7%; this stimulation is significantly (P<0.01) lowered to 13.1±1.9% by the simultaneous presence of CP99994. The same protocol is also used to characterize the sensitivity of Eledoisin stimulation to 0.1 μM SR48968 or 0.1 μM SB222200. SR48968 significantly (P < 0.01) lower the stimulation by Eledoisin, while SB222200 has no effect. Eledoisin stimulation is reduced by CP99994 and SR48968, NK1 and NK2 antagonists, respectively.

In Vivo:

Eledoisin (Eledone peptide; 0.1-1 nmol/kg) injected into rats produces a biphasic cardiovascular response that consists of an initial fall of systemic blood pressure (8-15 mm Hg) followed by a rise (20-22 mm Hg). Intracerebroventricular injection of Eledoisin produces an enhancement of grooming and scratching behavior in mice.

Products are for research use only. Not for human use.